OmniAb® Platform for High-Throughput Gene Cloning, Expression, Purification and Characterization
Gerry Rivera, Research Scientist, OmniAb Inc
OmniAb discovery technology incorporates a variety of transgenic animal platforms for the generation of diverse antibody repertoires. We have established a workflow to reformat hits from immunization campaigns into scFv-Fc, human IgG1, and other modalities for further characterization. We further expand on our high-throughput gene cloning, expression, purification, developability assessment and binding kinetics platform. We design double-stranded DNA fragments to perform Gibson assembly via a 96- well plate format to clone the desired IgGs. These clones are expressed in HEK Expi293F and ExpiCHO cells to produce the target antibodies, which are purified through a high-throughput 96-well format protein-A workflow. The developability profiles are obtained on purified IgG using nanoDSF and DLS. Characterization also includes a high throughput self-association assay using affinity-capture self-interaction nanoparticle spectroscopy (AC-SINS) (Xu et al., 2014). We further characterize the hits using Carterra LSA to determine binding kinetics, epitope and ligand competition profiles. As a result, we can screen quickly through many IgGs using our optimized high-throughput workflow to rank the therapeutic antibody candidates from a discovery campaign.
